Similarities and differences upon binding of naturally occurring Δ-tetrahydrocannabinol-derivatives to cannabinoid CB and CB receptors.

Pharmacol Res

Department of Biochemistry and Molecular Biomedicine, School of Biology, University of Barcelona, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CiberNed), Spanish National Institute of Health, Carlos iii, 28034 Madrid, Spain; School of Chemistry.

Published: December 2021


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

We have here assessed, using Δ-tetrahydrocannabinol (Δ-THC) for comparison, the effect of Δ-tetrahydrocannabinolic acid (Δ-THCA) and of Δ-tetrahydrocannabivarin (Δ9-THCV) that is mediated by human versions of CB, CB, and CB-CB receptor functional units, expressed in a heterologous system. Binding to the CB and CB receptors was addressed in living cells by means of a homogeneous assay. A biphasic competition curve for the binding to the CB receptor, was obtained for Δ-THCV in cells expressing the two receptors. Signaling studies included cAMP level determination, activation of the mitogen-activated protein kinase pathway and ß-arrestin recruitment were performed. The signaling triggered by Δ-THCA and Δ-THCV via individual receptors or receptor heteromers disclosed differential bias, i.e. the bias observed using a given phytocannabinoid depended on the receptor (CB, CB or CB-CB) and on the compound used as reference to calculate the bias factor (Δ-THC, a selective agonist or a non-selective agonist). These results are consistent with different binding modes leading to differential functional selectivity depending on the agonist structure, and the state (monomeric or heteromeric) of the cannabinoid receptor. In addition, on studying Gi-coupling we showed that Δ-THCV and Δ-THCA and Δ-THCV were able to revert the effect of a selective CB receptor agonist, but only Δ9-THCV, and not Δ9-THCA, reverted the effect of arachidonyl-2'-chloroethylamide (ACEA 100 nM) a selective agonist of the CB receptor. Overall, these results indicate that cannabinoids may have a variety of binding modes that results in qualitatively different effects depending on the signaling pathway that is engaged upon cannabinoid receptor activation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2021.105970DOI Listing

Publication Analysis

Top Keywords

receptor
8
Δ-thca Δ-thcv
8
selective agonist
8
binding modes
8
cannabinoid receptor
8
binding
5
agonist
5
similarities differences
4
differences binding
4
binding naturally
4

Similar Publications

Resolve and regulate: Alum nanoplatform coordinating STING availability and agonist delivery for enhanced anti-tumor immunotherapy.

Biomaterials

September 2025

Key Laboratory of Biopharmaceutical Preparation and Delivery, Institute of Process Engineering, Chinese Academy of Sciences, Beijing, 100190, PR China; University of Chinese Academy of Sciences, Beijing, 100049, PR China. Electronic address:

The stimulator of interferon genes (STING) pathway represents a promising target in cancer immunotherapy. However, the clinical translation of cyclic dinucleotide (CDN)-based STING agonists remains hindered by insufficient formation of functional CDN-STING complexes. This critical bottleneck arises from two interdependent barriers: inefficient cytosolic CDN delivery and tumor-specific STING silencing via DNA methyltransferase-mediated promoter hypermethylation.

View Article and Find Full Text PDF

The ability of parasitoid wasps to precisely locate hosts in complex environments is a key factor in suppressing pest populations. Chemical communication plays an essential role in mediating insect behaviors such as locating food sources, hosts, and mates. Odorant receptors (ORs) are the key connection between external odors and olfactory nerves.

View Article and Find Full Text PDF

Transcutaneous devices such as dental implants frequently fail due to infections at their interfaces with epithelial tissues. These infections are facilitated by the lack of integration between the devices and the surrounding soft tissues. This study aims to improve epithelial integration through surface modification of a transcutaneous implant material (polyetheretherketone (PEEK)).

View Article and Find Full Text PDF

Synthesis and Evaluation of Phenoxybenzylpiperidinyl Analogues as Agonists of the Chemokine Receptor CCR8.

Chem Biodivers

September 2025

Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular, Structural and Translational Virology Research Group, KU Leuven, Leuven, Belgium.

The human chemokine receptor 8 (CCR8) received attention as target for the treatment of various autoimmune disorders. Phenoxybenzylpiperidine analogues are known to act as CCR8 agonists, although their structure-activity relationship (SAR) has been studied to a limited extent. In this study, the SAR of phenoxybenzylpiperidinyl analogues was explored in a systematic way by fusion or insertion of various heterocyclic groups on the piperidinyl ring, yielding a set of 21 novel phenoxybenzylpiperidinyl derivatives.

View Article and Find Full Text PDF

20(R)-ginsenoside Rg3 Inhibits Neuroinflammation Induced by Cerebral Ischemia/Reperfusion Injury by Regulating the Toll-Like Receptor 4/Myeloid Differentiation Factor-88/Nuclear Factor Kappa B Signaling Pathway.

Chem Biodivers

September 2025

School of Pharmaceutical Science, Yunnan Key Laboratory of Pharmacology for Natural Products/College of Modern Biomedical Industry, NHC Key Laboratory of Drug Addiction Medicine, Kunming Medical University, Kunming, P. R. China.

20(R)-ginsenoside Rg3 can reduce the effects of oxidative stress and cell death in cerebral ischemia‒reperfusion injury (CIRI). Neuroinflammation is crucial post-CIRI, but how 20(R)-Rg3 affects ischemia‒reperfusion-induced neuroinflammation is unclear. To study 20(R)-Rg3's effects on neuroinflammation and neuronal preservation in stroke models and explore toll-like receptor 4/myeloid differentiation factor-88/nuclear factor kappa B (TLR4/MyD88/NF-κB) pathway mechanisms.

View Article and Find Full Text PDF